TECHNETIUM TC-99M MEDRONATE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Jubilant	DRAXIMAGE MDP-10	technetium tc-99m medronate	INJECTABLE;INJECTION	018035	NDA	Jubilant DraxImage Inc., dba Jubilant Radiopharma	65174-660-30	30 INJECTION, POWDER, FOR SOLUTION in 1 CARTON (65174-660-30)	2004-02-27
Jubilant	DRAXIMAGE MDP-25	technetium tc-99m medronate	INJECTABLE;INJECTION	018035	NDA	Jubilant DraxImage Inc., dba Jubilant Radiopharma	65174-660-30	30 INJECTION, POWDER, FOR SOLUTION in 1 CARTON (65174-660-30)	2004-02-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 3, 2025

Introduction

Technetium-99m Medronate (Tc-99m Medronate) is a radiopharmaceutical agent widely used in nuclear medicine for bone imaging procedures to diagnose skeletal abnormalities, metastatic bone disease, and infections. As a diagnostic agent with a critical role in clinical settings, the supply chain of Tc-99m Medronate is vital for healthcare providers globally. Given its short half-life and dependence on specialized production, understanding the key suppliers responsible for its manufacturing and distribution is essential for stakeholders in pharmaceutical, healthcare, and supply chain sectors.

Production of TechNETIUM-99m Medronate

Tc-99m Medronate is produced by radiolabeling Medronate compounds with Technetium-99m, a radioisotope derived from Molybdenum-99 (Mo-99). The process requires sophisticated nuclear reactors or generators, particularly Mo-99/Tc-99m generators, to produce Tc-99m at medical-grade purity. Therefore, top suppliers are primarily involved in generating Mo-99 and manufacturing Tc-99m generators, along with the final radiopharmaceutical assembly.

Leading Suppliers of Mo-99/ Tc-99m Generators

1. Nordion (Canada)

Nordion, a prominent player in the nuclear medicine supply chain, produces Mo-99/ Tc-99m generators used globally. Its Technetium-99m generators derive from high-quality Mo-99 supplied by nuclear reactors. Nordion's longstanding reputation and extensive distribution network make it a key supplier in this space.

2. Curium (France)

Curium supplies Mo-99 derived from LEU (Low Enriched Uranium) and HEU (High Enriched Uranium) reactors. Their Mo-99 generators are widely used in North America and Europe, offering reliable supply chains for Tc-99m radiopharmaceuticals, including Medronate.

3. GE Healthcare (USA)

A significant player in nuclear medicine, GE Healthcare produces advanced Mo-99 generators and offers a variety of Tc-99m kits. Their global distribution network supports consistent supply services for Tc-99m Medronate.

4. SHINE Medical Technologies (USA)

Emerging as a notable producer, SHINE manufactures Mo-99 from accelerator-based processes aimed at reducing nuclear proliferation risks and improving supply stability. They are expected to be major players in the near future.

5. Covidien / Mallinckrodt (Ireland/USA)

Part of the Mallinckrodt portfolio, Covidien historically supplied Mo-99 generators, with a robust manufacturing base in Ireland. Their products serve as a foundational source for Tc-99m radiopharmaceuticals globally.

Manufacturers Specializing in Tc-99m Medronate

While many suppliers provide Mo-99 generators, the actual formulation of Tc-99m Medronate involves compounding laboratories and pharmaceutical companies specialized in radiopharmaceutical manufacturing.

1. Bracco Diagnostics (USA/Italy)

Bracco is a foremost manufacturer of radiopharmaceuticals, including Tc-99m Medronate kits. Their products are available worldwide, meeting stringent regulatory standards.

2. Jubilant DraxImage (Canada)

Jubilant DraxImage produces radiopharmaceutical kits, including Tc-99m Medronate, often collaborating with hospitals and radiopharmacies to facilitate timely access.

3. Lantheus Medical Imaging (USA)

Lantheus is a major producer of nuclear imaging agents, offering Tc-99m Medronate kits with a comprehensive distribution network across North America and Europe.

4. Advanced Accelerator Applications (France)

This company develops and supplies radiopharmaceuticals, including bone imaging agents like Tc-99m Medronate, emphasizing high purity and quality standards.

Distribution and Regional Supply Challenges

Global supply of Tc-99m Medronate hinges on the stability of Mo-99 production, which has historically been constrained by reactor outages and geopolitical considerations. The reliance on aging nuclear reactors, primarily in Europe and North America, has prompted efforts to diversify supply chains, including accelerator-based Mo-99 production.

Regional Suppliers & Challenges:

North America: Dominated by GE Healthcare, Nordion, and Jubilant DraxImage. Supply stability heavily depends on U.S. and Canadian reactor operations.
Europe: Suppliers like Covidien, IRE, and Curium play vital roles; however, reactor shutdowns impact availability.
Asia and Other Regions: Growing local production initiatives, yet they lag in scale compared to Western markets.

Emerging Trends and Future Supply Dynamics

The global push for sustainable and proliferation-resistant production methods has led to increased investment in accelerator-produced Mo-99, promising more robust supply chains and regional independence. Entities like SHINE and Raytheon are pioneering such efforts, potentially reducing dependency on traditional reactors.

Additionally, the development and validation of alternative radiopharmaceuticals and imaging agents are gradually diversifying the landscape, though Tc-99m Medronate remains the standard for bone imaging.

Key Considerations for Stakeholders

Supply Security: Dependence on aging reactors necessitates diversification and investment in new production methods.
Regulatory Compliance: Suppliers must adhere to international standards (e.g., U.S. Pharmacopeia, EMA) ensuring product safety and efficacy.
Pricing and Accessibility: Market dynamics influence the cost and global availability of Tc-99m Medronate, calling for strategic procurement planning.
Innovation: Advances in generator technology and radiochemistry are enhancing supply resilience and safety profiles.

Conclusion

A complex, multilevel supply chain underpins the availability of Tc-99m Medronate, involving Mo-99 production, generator manufacturing, and final radiopharmaceutical formulation. Leading suppliers such as Nordion, Curium, GE Healthcare, and Bracco play pivotal roles, supported by industry shifts toward accelerator-based production. Ensuring an uninterrupted supply chain requires active monitoring of reactor statuses, regulatory landscapes, and emerging technological alternatives.

Key Takeaways

The supply of Tc-99m Medronate depends on the production of Mo-99, predominantly through nuclear reactors operated by companies like Nordion, Curium, and GE Healthcare.
Accelerator-based Mo-99 production is poised to enhance supply stability and reduce geopolitical risks.
Major radiopharmaceutical manufacturers, including Bracco and Lantheus, formulate and distribute Tc-99m Medronate kits globally.
Supply chain disruptions predominantly stem from reactor outages; diversification and new technologies are key to future resilience.
Regulatory standards and quality assurance are critical in maintaining the safety and efficacy of Tc-99m Medronate for diagnostic use.

FAQs

1. Who are the primary producers of Mo-99 used in Tc-99m Medronate?
Main producers include Nordion, Curium, and GE Healthcare, with emerging players like SHINE and Raytheon investing in accelerator-based technologies as alternatives.

2. How does the supply of Tc-99m Medronate impact healthcare delivery?
Limited or disrupted supply can delay diagnostic procedures, affecting patient outcomes. Ensuring reliable supply chains is crucial for timely diagnostics.

3. Are there regional differences in the availability of Tc-99m Medronate?
Yes. North America and Europe rely heavily on aging reactors, while emerging regional producers aim to improve local availability, especially through accelerator technologies.

4. What are the future trends affecting Tc-99m Medronate supply?
Increased adoption of accelerator-produced Mo-99, development of alternative imaging agents, and international collaborations aim to improve supply stability.

5. How are regulatory agencies supporting the stability of Tc-99m Medronate supply?
Agencies like the FDA and EMA set quality standards for radiopharmaceuticals and support initiatives to diversify and strengthen supply chains through approvals of new production methods.

References

[1] International Atomic Energy Agency. "Supply and Demand of Molybdenum-99." IAEA, 2021.
[2] Nuclear Medicine Suppliers. "Global Market Report for Nuclear Imaging Agents." Industry Publications, 2022.
[3] U.S. Food and Drug Administration. "Regulations for Radiopharmaceutical Manufacturing," 2022.
[4] Society of Nuclear Medicine and Molecular Imaging. "Advances in Radioisotope Production," 2022.
[5] Bloomberg Intelligence. "Global Nuclear Medicine Market Trends," 2023.

Suppliers and packagers for generic pharmaceutical drug: TECHNETIUM TC-99M MEDRONATE